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Herpes simplex viral disease is an important cause of morbidity and mortality in man. Although the development of very
effective nucleoside analogs with a high therapeutic index has greatly improved the clinical management of herpetic
infections, the emergence of drug-resistant viral strains has become a cause of serious concern both because of its clinical
implications and in terms of viral ecology. The present report is the first demonstration of the in vivo protective activity of
a type-common human recombinant monoclonal antibody derived from a combinatorial antibody library. Athymic nude mice
were infected with HSV type 1 either intracutaneously in the flank or by corneal scarification. Beside reducing mortality
rates when administered before infection, the antibody dramatically and significantly prolonged survival times (P  0.0001)
when administered up to 24 hr postinfection, a time when the virus had already reached the peripheral nervous system.
This suggests that the antibody may act, at least in part, by interfering with axonal transport of the virus and/or with viral
expression. These results indicate that human recombinant antibodies isolated by antigen selection from combinatorial
libraries can be effective in vivo. Such antibodies could complement antiviral chemotherapy and represent valuable tools
for the prophylaxis of infections by the herpes simplex viruses. q 1996 Academic Press, Inc.
Primary and secondary manifestations of infections Furthermore, the emergence of drug-resistant
strains of HSV in immunosupressed patients is a majorwith herpes simplex viruses (HSVs) are among the most
problem associated with prolonged or repeated anti-prevalent human maladies (1, 2). Although the most com-
herpetic therapy and represents a serious concern inmon clinical presentation of HSV infections are vesicular
terms of both clinical management and viral ecologyeruptions of the skin and mucous membranes, these
(5 – 9). In one study the incidence of resistance toviruses also cause severe diseases, often of difficult clin-
acyclovir, the most commonly employed antiherpeticical management, which include keratitis, encephalitis,
drug, exceeded 20% of HSV isolates from immunode-and disseminated illness in the newborn (1). Further-
pressed individuals exposed to the drug (6). Prolongedmore, the HSVs are among the wide range of bacterial,
or repeated treatment with foscarnet or with the nowviral, fungal, and protozoal organisms which cause op-
infrequently employed vidarabine has also beenportunistic infections in patients with AIDS and in pa-
shown to induce resistance (5, 7). These latter drugstients who are immunosuppressed because of other iat-
induce DNA polymerase mutations which often conferrogenic or pathologic reasons, such as organ trans-
resistance to multiple drugs (5, 7, 10, 11).plantation or hematologic malignancies (3, 4). Mucous
These observations underscore the importance of ex-and cutaneous lesions, in these patients, tend to become
ploring new and alternative prophylactic and therapeuticprogressive and persistent as the immunodeficiency be-
tools. Although in most individuals natural immunity pro-comes more severe, often resulting in chronic and intrac-
vides only partial protection from recurrence and reinfec-table manifestations (3, 4). HSV infections also represent
tion, the host immune response plays an unquestionablean occupational hazard for dentists, dental technicians,
role in the recovery from primary HSV infections and inrespiratory care workers, and other persons with fre-
the establishment and maintenance of HSV latency (1).quent contact with potentially infected mucous mem-
Recently it was demonstrated that therapeutic vaccina-branes (2).
tion can be effective in reducing the incidence of recur-
rent episodes of reactivation in experimental animals as1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (619) 554-6412. well as in humans (12, 13). However, therapeutic vaccina-
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tion is not feasible when active immunization cannot be by affinity chromatography over a column of immobilized
anti-human Fab according to standard techniques.elicited (i.e., in the immunocompromised), or in situations
in which an immediate therapeutic action is desired (e.g., We have utilized two established routes of infection:
intracutaneous inoculation in the flank (22, 23) and cor-encephalitis, neonatal herpes, et cetera). If panels of
powerful human monoclonal antibodies were available, neal infection (24, 25). The former model induces the
establishment of HSV infection in the dorsal root gangliapassive immunization could represent a valuable prophy-
lactic tool as well as a complement to antiviral chemo- by axonal spread of the virus, followed by the appearance
of zoster-like cutaneous lesions by centripetal spreading.therapy (14). Because of their transferability and safety,
human antibodies are among the immune mediators with In athymic nude mice, HSV also disseminates systemi-
cally and to the CNS and the infection is lethal (22, 23).the greatest attraction as therapeutic tools (15). Potent
human monoclonal antibodies or monoclonal antibody This route of infection produces a progressive clinical
picture which allows for reproducible clinical scoring ofcocktails are theoretically superior to polyclonal sera
since protective antibodies may be only a minor compo- the animals. The corneal infection route causes infection
of the trigeminal ganglia followed, in athymic nude mice,nent in the natural host response and because infection-
enhancing antibodies may also be present in polyclonal by centripetal spread to the CNS which results in a fatal
herpetic encephalitis. Female homozygous mice 5 to 6sera (15). In addition, antibodies present no risk of cross-
resistance if used in combination with chemotherapy weeks of age were infected either in the flank or in the
cornea with 5 1 104 PFU of HSV-1 strain F. Animals weresince they act through completely unrelated mecha-
nisms. anesthetized with methoxyflurane (Metofane, Pitman –
Moore, Mundelein, IL). For flank inoculation, the skinWe have isolated human monoclonal antibodies
against HSV from combinatorial Fab libraries (16–18). was scarified with a 23-gauge needle 10 times in parallel
horizontal lines and 10 more times perpendicularly, andHuman monoclonal antibodies against HSV have also
been obtained with conventional techniques (19) as well virus applied in a 10-ml drop of tissue culture medium.
Infected animals were observed daily and their clinicalas by humanization of murine antibodies (20). However,
our approach allows for the generation of large panels of status was scored as follows: 0, no lesion; 1–2, localized
lesion 3 mm; 3, localized lesion 3–6 mm; 4, localizedmonoclonal antibodies (17) with the potential to establish
cocktails of antibodies to exploit their additive and syner- lesion 6 mm; 5–6, mild zoster; 8, zoster with systemic
signs (i.e., splenomegaly, wasting); 10, severe zoster, se-gistic qualities. One of our antibodies, an IgG1 specific
for glycoprotein D (gD), proved to be a very potent neu- vere systemic signs, death. For corneal inoculation the
cornea was gently scarified in the same fashion de-tralizer of both HSV type 1 (HSV-1) and type 2 (HSV-2)
as a Fab fragment and was capable of inhibiting cell-to- scribed for the flank, and the viral inoculum applied in a
2-ml drop. A dose response curve was obtained withcell transmission of these viruses in vitro (16). In addition,
ongoing experiments suggest that this antibody acts animals infected intracutaneously in the flank 24 hr after
the intraperitoneal (ip) administration of 450, 150, 50, orthrough a first-order kinetics and is capable of neutraliz-
ing low-passage clinical isolates of both HSV-1 and -2 16.7 mg of antibody. Six animals or more were used for
each point of the dose response curve. A set of flank-with an 80% plaque reduction at 180–220 ng/ml (our
unpublished observations). In the present report we de- infected animals was treated ip 24 hr before infection, at
the time of infection (within 1 hr postinfection), or 24 hrscribe the ability of this antibody, as a whole IgG1 mole-
cule, to protect athymic nude mice from HSV-1 infections. postinfection with 150 mg of antibody. This dose very
close to the ED50 was selected so that a large enoughHSV-1 strain F (ATCC) was propagated in Vero cells
and titered by conventional plaque assay on monolayers number of succumbing animals could be obtained even
when the antibody was administered 24 hr before infec-of the same cell line. Female homozygous athymic mice
6–8 weeks old with a Balb/c genetic background tion in order to allow for the statistical comparison of
survival times in the different treatment groups. Corneallyweighing about 25 g were obtained from the breeding
colony of The Scripps Research Institute Department of infected animals were also treated at the time of infection
with 150 mg of antibody ip. Ganglionic viral yields in theAnimal Resources. Animals were kept according to stan-
dard conditions and observed for 2 weeks before being course of infection were not determined. Animals were
monitored for a month and surviving mice were thenemployed in the experiments. One mouse was discarded
during the observation period for displaying an apparent sacrificed. Data were analyzed using analysis of variance
(ANOVA) followed by a post-hoc Sheffe´ F test.tumor on the snout. The antibody used for this study,
HSV8, is the whole-antibody derivative of Fab AC8, a Passively transferred human recombinant antibody
HSV8 had a marked effect on the survival of infectedtype-common anti-gD which was isolated by antigen se-
lection from a phage display library (16). The construction mice. The dose response curve revealed a 50% survival
point slightly below the dose of 150 mg (about 6 mg/kg),of HSV8 from Fab AC8 and its expression in CHO cells
(not shown) were carried out as previously described and 7/16 animals succumbed in this dose group. The
ED50 calculated with the method of Reed and Muench(21). HSV8 was purified from tissue culture supernatant
/ m4655$7655 12-04-95 07:40:26 vira AP-Virology
103SHORT COMMUNICATION
as did 2 animals (20%) injected with the antibody at the
time of infection and 1 animal (11%) that was treated 24
hr postinfection (Figs. 2 and 3). In the antibody-treated
animals which eventually succumbed, the course of dis-
ease appeared delayed compared to that of the un-
treated controls (Fig. 3) and a statistically significant dif-
ference in survival times from those of the control group
was observed by ANOVA. The average survival time in
the control group was 7.9 days ({0.433), while it was
17.8 days ({0.97) in the group treated 24 hr before infec-
tion, 19.375 days ({1.034) in the group treated at the
time of infection, and 16.875 days ({1.342) in the group
treated 24 hr postinfection. Post-hoc Sheffe’ F test analy-FIG. 1. Survival dose response curve with HSV8, the human mono-
sis revealed that while survival times of the treated ani-clonal antibody used in the study of mice challenged with HSV-1.
Slightly over 50% of animals injected with 150 mg of the antibody 24 mals that succumbed all differed significantly from those
hr prior to an intradermic challenge in the flank survived. The ED50 was of the control group (P 0.0001), intriguingly, they did not
determined to be 128.3 mg/mouse with the method of Reed and Muench statistically differ among the different treatment groups (P
(about 5 mg/kg).  0.05). For the corneally infected animals, 7 of 8 control
animals inoculated in the cornea (87.5%) died, while only
was 128.3 mg (about 5 mg/kg) (Fig. 1). We then investi- 2 (25%) of the corneally inoculated animals that were
gated the ability of the antibody to alter the clinical course treated with 150 mg of the antibody at the time of inocula-
of the infection in animals treated 24 hr before the chal- tion succumbed to infection (Fig. 2). The high survival
lenge, at the time of infection, or 24 hr postinfection. rate among corneally inoculated animals treated with the
Control animals inoculated in the flank developed a ste- antibody did not allow for statistical comparison of the
reotyped disease course (Figs. 2 and 3). The clinical survival time. Regardless of inoculation route, animals
presentation was characterized by the appearance of which developed skin signs consistent with HSV infec-
localized skin lesions by Days 2–3 postinfection which tion (flank zoster or ocular–trigeminal zoster) eventually
evolved into zoster-like lesions by Days 4–6 (Fig. 3). In succumbed.
the following 2–3 days, all control animals developed a The role of the humoral immune response in experi-
picture of severe zoster accompanied by systemic signs mental HSV infections is well documented, as is the
such as wasting, hypomobility, and marked splenomeg- ability of both autologous and heterologous monoclonal
aly and succumbed within 10 days after inoculation (Figs. antibodies and certain polyclonal animal sera to confer
2 and 3). Fifty percent of the animals which received 150 protection in laboratory animals (22, 26 – 29, 31). There
is also indirect evidence that antibody to HSV may pre-mg of the antibody 24 hr prior to the inoculation survived
FIG. 2. Mortality among antibody-treated and untreated athymic nude mice infected with HSV-1 either intracutaneously in the flank skin (A) or by
the corneal route (B). Treated animals received 150 mg of the HSV8 antibody l.P.
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FIG. 3. Clinical course of athymic nude mice infected with HSV-1 intracutaneously in the flank. (A) Unprotected controls; (B) animals treated 24
hr before infection; (C) animals treated at the time of infection; (D) animals treated 24 hr postinfection. Infected animals were observed daily and
their clinical status was scored as follows: 0, no lesion; 1–2, localized lesion 3 mm; 3, localized lesion 3–6 mm; 4, localized lesion 6 mm; 5–
6, mild zoster; 8, zoster with systemic signs (i.e., splenomegaly, wasting); 10, severe zoster, severe systemic signs, death.
vent or modify human disease. The incidence of neona- These data notwithstanding, human immune serum has
shown little or no capacity to confer protection in pas-tal herpes is 30 – 50% in neonates born vaginally to
mothers with primary herpetic infections while it is only sive immunization either in man or in animal models (1,
26, 30). This failure may mean that protective antibodiesto 1 – 3% in neonates born vaginally to mothers with
recurrent manifestations, presumably due to the pas- against HSV and other viral pathogens are present only
as minor components of the natural immune responsesive transfer of protective antibodies transplacentally to
the fetus (30). In the older child and in the adult, al- and a crucial protective role is restricted to a limited
number of epitopes (22, 26). If this hypothesis is correct,though herpetic recurrences are often seen despite the
presence of neutralizing antibodies in the serum, the it will be critical to isolate and characterize the protec-
tive antibodies generated in the course of the naturalincidence and severity of HSV manifestations appear
to be inversely correlated with antibody responses (2). human immune response to explore the protective
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HSV activity in vivo are still poorly understood. Some
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